Research is a central focus of UTMB’s Division of Allergy and
Immunology. Since the creation of the division in the early 1970s, it
has been one of the region's premier research-oriented allergy centers.
Our research focuses on advancing the understanding of allergic and
immunologic disorders, as well as improving measures for diagnosis and
treatment. Clinical trials are carried out under strict guidelines with
great attention to participant safety.
Individuals choose to participate in clinical research for many
reasons. Some like the idea of being able to receive treatment with
promising therapies before they are approved by the Food and Drug
Administration for widespread commercial use. Others have tried
conventional treatments and are in search of a new option. Still others
may participate in clinical research in efforts to advance science and
medicine.
We currently are conducting studies on hereditary angioedema, ACE inhibitor-induced angioedema, asthma, and immunodeficiencies. New studies are added frequently; call to check with us about our latest research and trials.
Available Resources
UTMB Health is home to several unique facilities and programs that
support clinical research and provide world class clinical and research
opportunities.
Clinical Research Center
Child Health Research Center
Research Pharmacy
Aerospace Medicine Program
Affiliation with Shriners Burns Hospital
WHO Collaborating Center for Tropical Diseases
Institute for Translational Sciences
The ITS is the academic home of a five-year, $21.5 million
Clinical Translational Sciences Award (CTSA) by the National Institutes
of Health– National Center for Research Resources. The National CTSA
Consortium, which currently includes 46 institutions, is working to
improve human health by transforming the research and training
environment to enhance the efficiency and quality of clinical and
translational research.
NIH NHLBI Proteomics Center
UTMB is one of seven institutions which are part of a new
proteomics program launched by the NHLBI on August 15, 2010.
Collectively, the participating centers were awarded $83.5 million. UTMB
has been a part of the NHLBI Proteomics Initiative since 2002. The new
network consists of Boston University, Johns Hopkins University,
Massachusetts General Hospital, Stanford University, the University of
California-Los Angeles, the University of Texas Health Sciences Center
at San Antonio, and UTMB Health.
Some of the pioneering concepts and research activities undertaken by our team include:
- Identification of CC chemokines as IgE-independent histamine-releasing factors
- The use of CpG for treatment for Th2 inflammation and asthma
- Identification of pollen NADPH oxidase as a critical player in allergic airway inflammation
- Identification of mitochondrial proteins and their role in allergic inflammation
- Bronchscopy & BAL studies in patients with allergic asthma subjects for biomarkers
- Examination of relationship between food allergy and respiratory allergy
- Defining the role of xenoestrogens in asthma and other allergic disorders
We currently are conducting studies on hereditary angioedema, asthma,
and immunodeficiencies. New studies are added frequently; call to check
with us about our latest research and trials.
For more information about research studies and clinical trials, please contact us.